• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Richard M. Stone, MD


  • Marcucci G, Maharry KS, Metzeler KH, Volinia S, Wu YZ, Mrózek K, Nicolet D, Kohlschmidt J, Whitman SP, Mendler JH, Schwind S, Becker H, Eisfeld AK, Carroll AJ, Powell BL, Kolitz JE, Garzon R, Caligiuri MA, Stone RM, Bloomfield CD.Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients.J Clin Oncol. 2013 May 6.
  • Leblebjian H, Deangelo DJ, Skirvin JA, Stone RM, Wadleigh M, Werner L, Neuberg DS, Bartel S, McDonnell AM.Predictive factors for all-trans retinoic acid-related differentiation syndrome in patients with acute promyelocytic leukemia.Leuk Res. 2013 May 1.
  • Stone RM.Consolidation Chemotherapy for Adults With AML in First Remission: Is There a Best Choice?.J Clin Oncol. 2013 Apr 29.
  • Stone RM.Highlights in acute myeloid leukemia from the 2012 meeting of the American Society of Hematology.Expert Rev Hematol. 2013 Apr;6(2):127-9.
  • Stone RM.Acute myeloid leukemia in first remission: to choose transplantation or not?.J Clin Oncol. 2013 Apr 1;31(10):1262-6.
  • Etchin J, Sanda T, Mansour MR, Kentsis A, Montero J, Le BT, Christie AL, McCauley D, Rodig SJ, Kauffman M, Shacham S, Stone R, Letai A, Kung AL, Thomas Look A.KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.British Journal of Haematology. 2013 Apr;161(1):117-27.
  • Weisberg E, Liu Q, Zhang X, Nelson E, Sattler M, Liu F, Nicolais M, Zhang J, Mitsiades C, Smith RW, Stone R, Galinsky I, Nonami A, Griffin JD, Gray N.Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells.PLoS ONE. 2013;8(2):e56473.
  • Nelson EA, Walker SR, Xiang M, Weisberg E, Bar-Natan M, Barrett R, Liu S, Kharbanda S, Christie AL, Nicolais M, Griffin JD, Stone RM, Kung AL, Frank DA.The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations.Genes Cancer. 2012 Jul;3(7-8):503-11.
  • Stone RM.Is it time to revisit standard post-remission therapy?.Best Pract Res Clin Haematol. 2012 Dec;25(4):437-41.
  • Brusic A, Hainz U, Wadleigh M, Neuberg D, Su M, Canning CM, Deangelo DJ, Stone RM, Lee JS, Mulligan RC, Ritz J, Dranoff G, Sasada T, Wu CJ.Detecting T-cell reactivity to whole cell vaccines: Proof of concept analysis of T-cell response to K562 cell antigens in CML patients.Oncoimmunology. 2012 Oct 1;1(7):1095-1103.
  • Attar EC, Johnson JL, Amrein PC, Lozanski G, Wadleigh M, Deangelo DJ, Kolitz JE, Powell BL, Voorhees P, Wang ES, Blum W, Stone RM, Marcucci G, Bloomfield CD, Moser B, Larson RA.Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502.J Clin Oncol. 2012 Nov 5.
  • Fathi AT, Sadrzadeh H, Borger DR, Ballen KK, Amrein PC, Attar EC, Foster J, Burke M, Lopez HU, Matulis CR, Edmonds KM, Iafrate AJ, Straley KS, Yen KE, Agresta S, Schenkein DP, Hill C, Emadi A, Neuberg DS, Stone RM, Chen YB.Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response.Blood. 2012 Oct 16.
  • Cai A, Keskin DB, Deluca DS, Alonso A, Zhang W, Zhang GL, Hammond NN, Nardi V, Stone RM, Neuberg D, Sidney J, Brusic V, Wu CJ.Mutated BCR-ABL Generates Immunogenic T-cell Epitopes in CML Patients.Clin Cancer Res. 2012 Oct 15;18(20):5761-72.
  • Vo TT, Ryan J, Carrasco R, Neuberg D, Rossi DJ, Stone RM, Deangelo DJ, Frattini MG, Letai A.Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML.Cell. 2012 Oct 12;151(2):344-55.
  • Mrózek K, Marcucci G, Nicolet D, Maharry KS, Becker H, Whitman SP, Metzeler KH, Schwind S, Wu YZ, Kohlschmidt J, Pettenati MJ, Heerema NA, Block AW, Patil SR, Baer MR, Kolitz JE, Moore JO, Carroll AJ, Stone RM, Larson RA, Bloomfield CD.Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia.J Clin Oncol. 2012 Sep 17.
  • O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE, Goorha S, Lancet J, Maness LJ, Marcucci G, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Tallman MS, Wang ES, Naganuma M, Gregory KM.Acute myeloid leukemia.J Natl Compr Canc Netw. 2012 Aug;10(8):984-1021.
  • Stock W, Johnson JL, Stone RM, Kolitz JE, Powell BL, Wetzler M, Westervelt P, Marcucci G, Deangelo DJ, Vardiman JW, McDonnell D, Mrózek K, Bloomfield CD, Larson RA.Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: Results of Cancer and Leukemia Group B Study 19802.Cancer. 2012 Jun 28.
  • O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Coutre SE, Damon LE, Foran JM, Goorha S, Maness LJ, Marcucci G, Maslak P, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Tallman MS, Wang ES.Acute myeloid leukemia.J Natl Compr Canc Netw. 2011 Mar;9(3):280-317.
  • Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, Silverman MH, Gilliland DG, Shorr J, Tefferi A.Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.J Clin Oncol. 2011 Mar 1;29(7):789-96.
  • Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, Foran JM, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, Nimer SD, O'Donnell MR, Schroeder MA, Shami PJ, Stone RM, Thompson JE, Westervelt P.Myelodysplastic syndromes.J Natl Compr Canc Netw. 2011 Jan;9(1):30-56.
  • Stone RM.New agents in post-remission therapy.Best Pract Res Clin Haematol. 2010 Dec;23(4):475-9.
  • Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, Rowe JM, Coutre S, Feusner JH, Gregory J, Couban S, Appelbaum FR, Tallman MS, Larson RA.Arsenic trioxide improves event-free and over-all survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.Blood. 2010 Nov 11;116(19):3751-7.
  • Whitman SP, Maharry K, Radmacher MD, Becker H, Mrózek K, Margeson D, Holland KB, Wu YZ, Schwind S, Metzeler KH, Wen J, Baer MR, Powell BL, Carter TH, Kolitz JE, Wetzler M, Moore JO, Stone RM, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD.FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.Blood. 2010 Nov 4;116(18):3622-6.
  • Fischer T, Stone RM, Deangelo DJ, Galinsky I, Estey E, Lanza C, Fox E, Ehninger G, Feldman EJ, Schiller GJ, Klimek VM, Nimer SD, Gilliland DG, Dutreix C, Huntsman-Labed A, Virkus J, Giles FJ.Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.J Clin Oncol. 2010 Oct 1;28(28):4339-45.
  • Weisberg E, Choi HG, Barrett R, Zhou W, Zhang J, Ray A, Nelson EA, Jiang J, Moreno D, Stone R, Galinsky I, Fox E, Adamia S, Kung AL, Gray NS, Griffin JD.Discovery and characterization of novel mutant FLT3 kinase inhibitors.Mol Cancer Ther. 2010 Sep;9(9):2468-77.
  • Housman E, Chang P, Lane SW, Blinder R, Galinsky I, Kesari S, Ho VT, Stone RM, Mullally A.CNS relapse in acute promyeloctyic leukemia.J Clin Oncol. 2010 Aug 20;28(24):e409-11.
  • Stone RM, Moser B, Sanford B, Schulman P, Kolitz JE, Allen S, Stock W, Galinsky I, Vij R, Marcucci G, Hurd D, Larson RA, .High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.Leuk Res. 2010 Aug 3.
  • Abel GA, Van Bennekom CM, Stone RM, Anderson TE, Kaufman DW.Classification of the myelodysplastic syndrome in a national registry of recently diagnosed patients.Leuk Res. 2010 Jul;34(7):939-41.
  • Motyckova G, Stone RM.The role of molecular tests in acute myelogenous leukemia treatment decisions.Curr Hematol Malig Rep. 2010 Apr;5(2):109-17. Review.
  • Steensma DP, Stone RM.Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes.Hematol Oncol Clin North Am. 2010 Apr;24(2):389-406. Review.
  • Rosenblatt J, Wu Z, Vasir B, Zarwan C, Stone R, Mills H, Friedman T, Konstantinopoulos PA, Spentzos D, Ghebremichael M, Stevenson K, Neuberg D, Levine JD, Joyce R, Tzachanis D, Boussiotis V, Kufe D, Avigan D.Generation of Tumor-specific T Lymphocytes Using Dendritic Cell/Tumor Fusions and Anti-CD3/CD28.J Immunother.;33(2):155-66.
  • Yoda A, Yoda Y, Chiaretti S, Bar-Natan M, Mani K, Rodig SJ, West N, Xiao Y, Brown JR, Mitsiades C, Sattler M, Kutok JL, DeAngelo DJ, Wadleigh M, Piciocchi A, Dal Cin P, Bradner JE, Griffin JD, Anderson KC, Stone RM, Ritz J, Foà R, Aster JC, Frank DA, Weinstock DM.Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):252-7.
  • Stone RM.Prognostic factors in AML in relation to (ab)normal karyotype.Best Pract Res Clin Haematol. 2009 Dec;22(4):523-8. Review.
  • Rhodes J, Amsterdam A, Sanda T, Moreau LA, McKenna K, Heinrichs S, Ganem NJ, Ho KW, Neuberg DS, Johnston A, Ahn Y, Kutok JL, Hromas R, Wray J, Lee C, Murphy C, Radtke I, Downing JR, Fleming MD, MacConaill LE, Amatruda JF, Gutierrez A, Galinsky I, Stone RM, Ross EA, Pellman DS, Kanki JP, Look AT.Emi1 maintains genomic integrity during zebrafish embryogenesis and cooperates with p53 in tumor suppression.Mol Cell Biol. 2009 Nov;29(21):5911-22.
  • Hahn CK, Berchuck JE, Ross KN, Kakoza RM, Clauser K, Schinzel AC, Ross L, Galinsky I, Davis TN, Silver SJ, Root DE, Stone RM, DeAngelo DJ, Carroll M, Hahn WC, Carr SA, Golub TR, Kung AL, Stegmaier K.Proteomic and genetic approaches identify Syk as an AML target.Cancer Cell. 2009 Oct 6;16(4):281-94.
  • Stone RM, DeAngelo DJ.Screens, iron, and leukemia.Blood. 2009 Oct 1;114(14):2857-8.
  • Borrello IM, Levitsky HI, Stock W, Sher D, Qin L, DeAngelo DJ, Alyea EP, Stone RM, Damon LE, Linker CA, Maslyar DJ, Hege KM.Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML).Blood. 2009 Aug 27;114(9):1736-45.
  • Apperley JF,Cortes JE,Kim DW,Roy L,Roboz GJ,Rosti G,Bullorsky EO,Abruzzese E,Hochhaus A,Heim D,de Souza CA,Larson RA,Lipton JH,Khoury HJ,Kim HJ,Sillaber C,Hughes TP,Erben P,Van Tornout J,Stone RM.Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial.J Clin Oncol. 2009 Jul 20;27(21):3472-9.
  • Abdel-Wahab O,Mullally A,Hedvat C,Garcia-Manero G,Patel J,Wadleigh M,Malinge S,Yao J,Kilpivaara O,Bhat R,Huberman K,Thomas S,Dolgalev I,Heguy A,Paietta E,Le Beau MM,Beran M,Tallman MS,Ebert BL,Kantarjian HM,Stone RM,Gilliland DG,Crispino JD,Levine RL.Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.Blood. 2009 Jul 2;114(1):144-7.
  • Stone RM.How I treat patients with myelodysplastic syndromes.Blood. 2009 Jun 18;113(25):6296-303. Review.
  • Weisberg E,Barrett R,Liu Q,Stone R,Gray N,Griffin JD.FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML.Drug Resist Updat. 2009 Jun;12(3):81-9. Review.
  • Corsello SM,Roti G,Ross KN,Chow KT,Galinsky I,Deangelo DJ,Stone RM,Kung AL,Golub TR,Stegmaier K.Identification of AML1-ETO modulators by chemical genomics.Blood. 2009 Jun 11;113(24):6193-205.
  • Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, Wadleigh M, DeAngelo DJ, Stone RM, Sakamaki H, Appelbaum FR, Döhner H, Antin JH, Soiffer RJ, Cutler C.Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.JAMA. 2009 Jun 10;301(22):2349-61. Review.
  • Kilpivaara O,Mukherjee S,Schram AM,Wadleigh M,Mullally A,Ebert BL,Bass A,Marubayashi S,Heguy A,Garcia-Manero G,Kantarjian H,Offit K,Stone RM,Gilliland DG,Klein RJ,Levine RL.A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.Nat Genet. 2009 Apr;41(4):455-9.
  • Wadleigh M,Stone RM.The role of myeloid growth factors in acute leukemia.J Natl Compr Canc Netw. 2009 Jan;7(1):84-91. Review.
  • O'Donnell MR,Appelbaum FR,Coutre SE,Damon LE,Erba HP,Foran J,Lancet J,Maness LJ,Marcucci G,Maslak PG,Millenson M,Moore JO,Ravandi F,Schuening F,Shami P,Smith BD,Stone RM,Tallman MS,Wang E,White FL.Acute myeloid leukemia.J Natl Compr Canc Netw. 2008 Nov;6(10):962-93. Review.
  • Stone RM.Are new agents really making a difference in MDS?.Best Pract Res Clin Haematol. 2008 Dec;21(4):639-46. Review.
  • Grinblatt DL,Yu D,Hars V,Vardiman JW,Powell BL,Nattam S,Silverman LR,de Castro C 3rd,Stone RM,Bloomfield CD,Larson RA.Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803).Cancer. 2009 Jan 1;115(1):84-93.
  • Fonseca C,Soiffer R,Ho V,Vanneman M,Jinushi M,Ritz J,Neuberg D,Stone R,DeAngelo D,Dranoff G.Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction.Blood. 2009 Feb 19;113(8):1681-8.
  • Greenberg PL,Attar E,Battiwalla M,Bennett JM,Bloomfield CD,DeCastro CM,Deeg HJ,Erba HP,Foran JM,Garcia-Manero G,Gore SD,Head D,Maness LJ,Millenson M,Nimer SD,O'Donnell MR,Saba HI,Shami PJ,Spiers K,Stone RM,Tallman MS,Westervelt P.Myelodysplastic syndromes.J Natl Compr Canc Netw. 2008 Oct;6(9):902-26.
  • Weisberg E,Roesel J,Bold G,Furet P,Jiang J,Cools J,Wright RD,Nelson E,Barrett R,Ray A,Moreno D,Hall-Meyers E,Stone R,Galinsky I,Fox E,Gilliland G,Daley JF,Lazo-Kallanian S,Kung AL,Griffin JD.Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells.Blood. 2008 Dec 15;112(13):5161-70.
  • Stone RM,DeAngelo DJ,Janosova A,Galinsky I,Canning C,Ritz J,Soiffer RJ.Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission.Am J Hematol. 2008 Oct;83(10):771-7.
  • Stone RM,Donohue KA,Stock W,Hars V,Linker CA,Shea T,Deangelo DJ,Marcucci G,Bloomfield CD,Larson RA.A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804.Cancer Chemother Pharmacol. 2009 Apr;63(5):859-64.
  • Kesari S,Drappatz J,Akar S,Vergilio JA,Wen PY,Soiffer RJ,Stone RM,Deangelo DJ.Recurrent acute promyelocytic leukemia presenting as a sacral nerve root mass.J Clin Oncol. 2008 Jul 1;26(19):3279-81.
  • Baer MR,George SL,Caligiuri MA,Sanford BL,Bothun SM,Mrozek K,Kolitz JE,Powell BL,Moore JO,Stone RM,Anastasi J,Bloomfield CD,Larson RA.Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.J Clin Oncol. 2008 Oct 20;26(30):4934-9.
  • Weisberg E, Wright RD, McMillin DW, Mitsiades C, Ray A, Barrett R, Adamia S, Stone R, Galinsky I, Kung AL, Griffin JD.Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells.Mol Cancer Ther. 2008 May;7(5):1121-9.
  • Wetzler M, Donohue KA, Odenike OM, Feldman EJ, Hurd DD, Stone RM, Westerfelt P, Bloomfield CD, Larson RA.Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia - Cancer and leukemia group B study 10107.Leuk Lymphoma. 2008 Apr 4:1-5.
  • Attar EC, De Angelo DJ, Supko JG, D'Amato F, Zahrieh D, Sirulnik A, Wadleigh M, Ballen KK, McAfee S, Miller KB, Levine J, Galinsky I, Trehu EG, Schenkein D, Neuberg D, Stone RM, Amrein PC.Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia.Clin Cancer Res. 2008 Mar 1;14(5):1446-54.
  • Ebert BL, Galili N, Tamayo P, Bosco J, Mak R, Pretz J, Tanguturi S, Ladd-Acosta C, Stone R, Golub TR, Raza A.An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome.PLoS Med. 2008 Feb;5(2):e35.
  • Loriaux MM, Levine RL, Tyner JW, Frohling S, Scholl C, Stoffregen EP, Wernig G, Erickson H, Eide CA, Berger R, Bernard OA, Griffin JD, Stone RM, Lee B, Meyerson M, Heinrich MC, Deininger MW, Gilliland DG, Druker BJ.High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia.Blood. 2008 May 1;111(9):4788-96.
  • Oliansky DM, Appelbaum F, Cassileth PA, Keating A, Kerr J, Nieto Y, Stewart S, Stone RM, Tallman MS, McCarthy PL Jr, Hahn T.The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review.Biol Blood Marrow Transplant. 2008 Feb;14(2):137-80. Review.
  • Weisberg E, Banerji L, Wright RD, Barrett R, Ray A, Moreno D, Catley L, Jiang J, Hall-Meyers E, Sauveur-Michel M, Stone R, Galinsky I, Fox E, Kung AL, Griffin JD.Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.Blood. 2008 Apr 1;111(7):3723-34.
  • Raponi M, Lancet JE, Fan H, Dossey L, Lee G, Gojo I, Feldman EJ, Gotlib J, Morris LE, Greenberg PL, Wright JJ, Harousseau JL, Lowenberg B, Stone RM, De Porre P, Wang Y, Karp JE.A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia.Blood. 2008 Mar 1;111(5):2589-96.
  • Kawano T, Ito M, Raina D, Wu Z, Rosenblatt J, Avigan D, Stone R, Kufe D.MUC1 oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic myelogenous leukemia cells.Cancer Res. 2007 Dec 15;67(24):11576-84.
  • Frohling S, Scholl C, Levine RL, Loriaux M, Boggon TJ, Bernard OA, Berger R, Dohner H, Dohner K, Ebert BL, Teckie S, Golub TR, Jiang J, Schittenhelm MM, Lee BH, Griffin JD, Stone RM, Heinrich MC, Deininger MW, Druker BJ, Gilliland DG.Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.Cancer Cell. 2007 Dec;12(6):501-13.
  • Deangelo DJ, Yu D, Johnson JL, Coutre SE, Stone RM, Stopeck AT, Gockerman JP, Mitchell BS, Appelbaum FR, Larson RA.Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: cancer and leukemia group B study 19801.Blood. 2007 Jun 15;109(12):5136-42.
  • Armand P, Kim HT, Deangelo DJ, Ho VT, Cutler CS, Stone RM, Ritz J, Alyea EP, Antin JH, Soiffer RJ.Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation.Biol Blood Marrow Transplant. 2007 Jun;13(6):655-64.
  • Stone RM.Novel therapeutic agents in acute myeloid leukemia.Exp Hematol. 2007 Apr;35(4 Suppl 1):163-6. Review.
  • Stone RM.Targeted agents in AML: much more to do.Best Pract Res Clin Haematol. 2007 Mar;20(1):39-48. Review.
  • Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA.Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.N Engl J Med. 2006 Dec 7;355(23):2408-17.
  • Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, Facon T, Goldberg SL, Cervantes F, Niederwieser D, Silver RT, Stone RM, Hughes TP, Muller MC, Ezzeddine R, Countouriotis AM, Shah NP.Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.Blood. 2007 Mar 15;109(6):2303-9.
  • Appelbaum FR, Rosenblum D, Arceci RJ, Carroll WL, Breitfeld PP, Forman SJ, Larson RA, Lee SJ, Murphy SB, O'Brien S, Radich J, Scher NS, Smith FO, Stone RM, Tallman MS.End points to establish the efficacy of new agents in the treatment of acute leukemia.Blood. 2007 Mar 1;109(5):1810-6.
  • Alyea EP, Kim HT, Ho V, Cutler C, DeAngelo DJ, Stone R, Ritz J, Antin JH, Soiffer RJ.Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.Biol Blood Marrow Transplant. 2006 Oct;12(10):1047-55.
  • DeAngelo DJ, Stone RM, Heaney ML, Nimer SD, Paquette RL, Klisovic RB, Caligiuri MA, Cooper MR, Lecerf JM, Karol MD, Sheng S, Holford N, Curtin PT, Druker BJ, Heinrich MC.Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics.Blood. 2006 Dec 1;108(12):3674-81.
  • Larson RA, Stone RM, Mayer RJ, Schiffer CA.Fifty years of clinical research by the leukemia committee of the cancer and leukemia group B.Clin Cancer Res. 2006 Jun 1;12(11 Pt 2):3556s-63s. Review.
  • Stock W, Yu D, Karrison T, Sher D, Stone RM, Larson RA, Bloomfield CD.Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples.Int J Oncol. 2006 May;28(5):1099-103.
  • Growney JD, Clark JJ, Adelsperger J, Stone R, Fabbro D, Griffin JD, Gilliland DG.Activation mutations of human c-KIT resistant to imatinib are sensitive to the tyrosine kinase inhibitor PKC412.Blood. 2005 Jul 15;106(2):721-4.
  • Haining WN, Cardoso AA, Keczkemethy HL, Fleming M, Neuberg D, DeAngelo DJ, Stone RM, Galinsky I, Silverman LB, Sallan SE, Nadler LM, Guinan EC.Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia.Exp Hematol. 2005 Mar;33(3):286-94.
  • Alyea EP, Kim HT, Ho VT, Cutler C, Gribben J, DeAngelo DJ, Lee SJ, Windawi S, Ritz J, Stone RM, Antin JH, Soiffer RJ.Comparative outcome of non-myeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients greater than fifty years of age.Blood. 2005 Feb 15;105(4):1810-4.
  • Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD, Grandin W, Lebwohl D, Wang Y, Cohen P, Fox EA, Neuberg D, Clark J, Gilliland DG, Griffin JD.Acute myeloid leukemia patients with an activating mutation in FLT3 respond to a small molecule FLT3 tyrosine kinase inhibitor, PKC412.Blood. 2005 Jan 1;105(1):54-60.
  • Farag SS, Ruppert AS, Mrzek K, Mayer RJ, Stone RM, Carroll AJ, Powell BL, Moore JO, Pettenati MJ, Koduru PR, Stamberg J, Baer MR, Block AW, Vardiman JW, Kolitz JE, Schiffer CA, Larson RA, Bloomfield CD.Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.J Clin Oncol. 2005 Jan 20;23(3):482-93.
  • Levine RL, Wadleigh M, Sternberg DW, Wlodarska I, Galinsky I, Stone RM, DeAngelo DJ, Gilliland DG, Cools J.KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32).Leukemia. 2005 Jan;19(1):27-30.
  • Gong J, Koido S, Kato Y, Tanaka Y, Chen D, Jonas A, Galinsky I, DeAngelo D, Avigan D, Kufe D, Stone R.Induction of anti-leukemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts.Leuk Res. 2004 Dec;28(12):1303-12.
  • Chen J, Deangelo DJ, Kutok JL, Williams IR, Lee BH, Wadleigh M, Duclos N, Cohen S, Adelsperger J, Okabe R, Coburn A, Galinsky I, Huntly B, Cohen PS, Meyer T, Fabbro D, Roesel J, Banerji L, Griffin JD, Xiao S, Fletcher JA, Stone RM, Gilliland DG.PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.Proc Natl Acad Sci U S A. 2004 Oct 5;101(40):14479-84.
  • Wadleigh M, DeAngelo DJ, Griffin JD, Stone RM.After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies.Blood. 2005 Jan 1;105(1):22-30.
  • Jiang J, Paez JG, Lee JC, Bo R, Stone RM, DeAngelo DJ, Galinsky I, Wolpin BM, Jonasova A, Herman P, Fox EA, Boggon TJ, Eck MJ, Weisberg E, Griffin JD, Gilliland DG, Meyerson M, Sellers WR.Identification and Characterization of a Novel Activating Mutation of the FLT3 Tyrosine Kinase in AML.Blood. 2004 Sep 15;104(6):1855-8.
  • DeAngelo DJ, Hochberg EP, Alyea EP, Longtine J, Lee S, Galinsky I, Parekkedon B, Ritz J, Antin JH, Stone RM, Soiffer RJ.Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.Clin Cancer Res. 2004 Aug 1;10(15):5065-71.
  • Sekeres MA, Stone RM, Zahrieh D, Neuberg D, Morrison V, De Angelo DJ, Galinsky I, Lee SJ.Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome.Leukemia. 2004 Apr;18(4):809-16.
  • Cools J, Stover EH, Boulton CL, Gotlib J, Legare RD, Amaral SM, Curley DP, Duclos N, Rowan R, Kutok JL, Lee BH, Williams IR, Coutre SE, Stone RM, DeAngelo DJ, Marynen P, Manley PW, Meyer T, Fabbro D, Neuberg D, Weisberg E, Griffin JD, Gilliland DG.PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease.Cancer Cell. 2003 May;3(5):459-69.
  • Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V, Alyea EP, Antin JH, Stone RM, Soiffer RJ, DeAngelo DJ.Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation.Blood. 2003 Sep 1;102(5):1578-82.
  • Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG.A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.N Engl J Med. 2003 Mar 27;348(13):1201-14.
  • Stone RM.Induction and postremission therapy: new agents.Leukemia. 2003 Mar;17(3):496-8.
  • Wu CJ, Neuberg D, Chillemi A, McLaughlin S, Hochberg EP, Galinsky I, DeAngelo D, Soiffer RJ, Alyea EP, Capdeville R, Stone RM, Ritz J.Quantitative monitoring of BCR/ABL transcript during STI-571 therapy.Leuk Lymphoma. 2002 Dec;43(12):2281-9.
  • Alyea EP, Weller E, Fisher DC, Freedman AS, Gribben JG, Lee S, Schlossman RL, Stone RM, Friedberg J, DeAngelo D, Liney D, Windawi S, Ng A, Mauch P, Antin JH, Soiffer RJ.Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation.Biol Blood Marrow Transplant. 2002;8(11):601-7.
  • Stone RM.Treatment of acute myeloid leukemia: state-of-the-art and future directions.Semin Hematol. 2002 Jul;39(3 Suppl 2):4-10.
  • Stone RM.New therapies in leukemia: renewed hope.J Hematother Stem Cell Res. 2002 Aug;11(4):583-7.
  • Soiffer RJ, Weller E, Alyea EP, Mauch P, Webb IL, Fisher DC, Freedman AS, Schlossman RL, Gribben J, Lee S, Anderson KC, Marcus K, Stone RM, Antin JH, Ritz J.CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors.J Clin Oncol. 2001 Feb 15;19(4):1152-9.
  • Schiffer CA, Miller K, Larson RA, Amrein PC, Antin JH, Zani VJ, Stone RM.A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia.Blood. 2000 Apr 15;95(8):2530-5.
  • Friedberg JW, Neuberg D, Stone RM, Alyea E, Jallow H, LaCasce A, Mauch PM, Gribben JG, Ritz J, Nadler LM, Soiffer RJ, Freedman AS.Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma.J Clin Oncol. 1999 Oct;17(10):3128-35.
  • Larson RA, Dodge RK, Linker CA, Stone RM, Powell BL, Lee EJ, Schulman P, Davey FR, Frankel SR, Bloomfield CD, George SL, Schiffer CA.A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111.Blood. 1998 Sep 1;92(5):1556-64.
  • Xiao S, Nalabolu SR, Aster JC, Ma J, Abruzzo L, Jaffe ES, Stone R, Weissman SM, Hudson TJ, Fletcher JA.FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome.Nat Genet. 1998 Jan;18(1):84-7.
  • Soiffer RJ, Fairclough D, Robertson M, Alyea E, Anderson K, Freedman A, Bartlett-Pandite L, Fisher D, Schlossman RL, Stone R, Murray C, Freeman A, Marcus K, Mauch P, Nadler L, Ritz J.CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission.Blood. 1997 Apr 15;89(8):3039-47.
  • Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P, Lee EJ, Moore JO, Powell BL, Schiffer CA.Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.N Engl J Med. 1995 Jun 22;332(25):1671-7.
  • Inhorn RC, Aster JC, Roach SA, Slapak CA, Soiffer R, Tantravahi R, Stone RM.A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity.Blood. 1995 Apr 1;85(7):1881-7.
  • Stone RM, Neuberg D, Soiffer R, Takvorian T, Whelan M, Rabinowe SN, Aster JC, Leavitt P, Mauch P, Freedman AS.Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma.J Clin Oncol. 1994 Dec;12(12):2535-42.
  • Stone RM, Bernstein SH, Demetri G, Facklam DP, Arthur K, Andersen J, Aster JC, Kufe D.Therapy with recombinant human erythropoietin in patients with myelodysplastic syndromes.Leuk Res. 1994 Oct;18(10):769-76.
  • Stone RM.Myelodysplastic syndrome after autologous transplantation for lymphoma: the price of progress.Blood. 1994 Jun 15;83(12):3437-40.
  • Stone RM, Spriggs DR, Arthur KA, Mayer RJ, Griffin J, Kufe DW.Recombinant human gamma interferon administered by continuous intravenous infusion in acute myelogenous leukemia and myelodysplastic syndromes.Am J Clin Oncol. 1993 Apr;16(2):159-63.
  • Stone RM, Imamura K, Datta R, Sherman ML, Kufe DW.Inhibition of phorbol ester-induced monocytic differentiation and c-fms gene expression by dexamethasone: potential involvement of arachidonic acid metabolites.Blood. 1990 Sep 15;76(6):1225-32.
  • Stone RM, Sariban E, Pettit GR, Kufe DW.Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells.Blood. 1988 Jul;72(1):208-13.
  • Stone RM, Maguire M, Goldberg MA, Antin JH, Rosenthal DS, Mayer RJ.Complete remission in acute promyelocytic leukemia despite persistence of abnormal bone marrow promyelocytes during induction therapy: experience in 34 patients.Blood. 1988 Mar;71(3):690-6.